{"id":8506,"date":"2026-02-10T12:53:24","date_gmt":"2026-02-10T16:53:24","guid":{"rendered":"https:\/\/www.terenos.ms.gov.br\/?p=8506"},"modified":"2026-02-10T12:53:24","modified_gmt":"2026-02-10T16:53:24","slug":"vacina-da-palivizumabe-e-nirsevimabe","status":"publish","type":"post","link":"https:\/\/www.terenos.ms.gov.br\/?p=8506","title":{"rendered":"Vacina da Palivizumabe e Nirsevimabe"},"content":{"rendered":"<p style=\"text-align: justify;\" data-start=\"129\" data-end=\"197\"><strong data-start=\"129\" data-end=\"197\">Prote\u00e7\u00e3o contra o V\u00edrus Sincicial Respirat\u00f3rio (VSR) em crian\u00e7as<\/strong><\/p>\n<p style=\"text-align: justify;\" data-start=\"199\" data-end=\"405\">O Palivizumabe \u00e9 um anticorpo monoclonal indicado para a preven\u00e7\u00e3o de infec\u00e7\u00f5es graves causadas pelo V\u00edrus Sincicial Respirat\u00f3rio (VSR), especialmente em crian\u00e7as que apresentam maior risco de complica\u00e7\u00f5es.<\/p>\n<h3 style=\"text-align: justify;\" data-start=\"407\" data-end=\"446\">Continuidade do uso do Palivizumabe<\/h3>\n<p style=\"text-align: justify;\" data-start=\"448\" data-end=\"507\">Devem concluir obrigatoriamente o esquema com Palivizumabe:<\/p>\n<ul style=\"text-align: justify;\" data-start=\"509\" data-end=\"742\">\n<li data-start=\"509\" data-end=\"742\">\n<p data-start=\"511\" data-end=\"742\">Crian\u00e7as prematuras nascidas com idade gestacional menor ou igual a 28 semanas e 6 dias, com idade inferior a 1 ano (at\u00e9 11 meses e 29 dias), que iniciaram o tratamento durante a sazonalidade de 2025 e permanecem eleg\u00edveis em 2026.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" data-start=\"744\" data-end=\"810\">Tamb\u00e9m devem concluir prioritariamente o esquema com Palivizumabe:<\/p>\n<ul style=\"text-align: justify;\" data-start=\"812\" data-end=\"1114\">\n<li data-start=\"812\" data-end=\"1114\">\n<p data-start=\"814\" data-end=\"902\">Crian\u00e7as com idade inferior a 2 anos (at\u00e9 1 ano, 11 meses e 29 dias) diagnosticadas com:<\/p>\n<ul data-start=\"905\" data-end=\"1114\">\n<li data-start=\"905\" data-end=\"980\">\n<p data-start=\"907\" data-end=\"980\">Doen\u00e7a pulmonar cr\u00f4nica da prematuridade (displasia broncopulmonar); ou<\/p>\n<\/li>\n<li data-start=\"983\" data-end=\"1114\">\n<p data-start=\"985\" data-end=\"1114\">Doen\u00e7a card\u00edaca cong\u00eanita com repercuss\u00e3o hemodin\u00e2mica comprovada;<br data-start=\"1051\" data-end=\"1054\" \/>que iniciaram o tratamento em 2025 e permanecem eleg\u00edveis.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<h3 style=\"text-align: justify;\" data-start=\"1116\" data-end=\"1138\">Local de aplica\u00e7\u00e3o<\/h3>\n<p style=\"text-align: justify;\" data-start=\"1140\" data-end=\"1172\">As aplica\u00e7\u00f5es s\u00e3o realizadas no:<\/p>\n<p style=\"text-align: justify;\" data-start=\"1174\" data-end=\"1310\"><strong data-start=\"1174\" data-end=\"1248\">Centro de Refer\u00eancia da Mulher \u2013 Atendimento Materno Infantil (CEM II)<\/strong><br data-start=\"1248\" data-end=\"1251\" \/>Telefone: (67) 2020-1590<br data-start=\"1275\" data-end=\"1278\" \/>E-mail: <a class=\"decorated-link cursor-pointer\" rel=\"noopener\" data-start=\"1286\" data-end=\"1310\">palivizumabecg@gmail.com<\/a><\/p>\n<hr data-start=\"1312\" data-end=\"1315\" \/>\n<h2 style=\"text-align: justify;\" data-start=\"1317\" data-end=\"1333\">Nirsevimabe<\/h2>\n<p style=\"text-align: justify;\" data-start=\"1334\" data-end=\"1378\"><strong data-start=\"1334\" data-end=\"1378\">Nova estrat\u00e9gia de prote\u00e7\u00e3o contra o VSR<\/strong><\/p>\n<p style=\"text-align: justify;\" data-start=\"1380\" data-end=\"1598\">Crian\u00e7as contempladas pelo protocolo e nascidas ap\u00f3s o t\u00e9rmino da sazonalidade de 2025 at\u00e9 o final de janeiro de 2026, que n\u00e3o receberam Palivizumabe em 2025, iniciaram o esquema com o anticorpo monoclonal Nirsevimabe.<\/p>\n<h3 style=\"text-align: justify;\" data-start=\"1600\" data-end=\"1657\">P\u00fablico-alvo da estrat\u00e9gia de resgate com Nirsevimabe<\/h3>\n<p style=\"text-align: justify;\" data-start=\"1659\" data-end=\"1666\">Inclui:<\/p>\n<ul style=\"text-align: justify;\" data-start=\"1668\" data-end=\"1884\">\n<li data-start=\"1668\" data-end=\"1782\">\n<p data-start=\"1670\" data-end=\"1782\">Crian\u00e7as prematuras com idade gestacional igual ou inferior a 36 semanas e 6 dias, com idade inferior a 6 meses;<\/p>\n<\/li>\n<li data-start=\"1783\" data-end=\"1884\">\n<p data-start=\"1785\" data-end=\"1884\">Crian\u00e7as com idade inferior a 24 meses (at\u00e9 1 ano, 11 meses e 29 dias) que apresentem comorbidades.<\/p>\n<\/li>\n<\/ul>\n<h3 style=\"text-align: justify;\" data-start=\"1886\" data-end=\"1915\">Comorbidades contempladas<\/h3>\n<ul style=\"text-align: justify;\" data-start=\"1917\" data-end=\"2113\">\n<li data-start=\"1917\" data-end=\"1971\">\n<p data-start=\"1919\" data-end=\"1971\">Imunodefici\u00eancias graves (cong\u00eanitas ou adquiridas);<\/p>\n<\/li>\n<li data-start=\"1972\" data-end=\"1990\">\n<p data-start=\"1974\" data-end=\"1990\">Fibrose c\u00edstica;<\/p>\n<\/li>\n<li data-start=\"1991\" data-end=\"2024\">\n<p data-start=\"1993\" data-end=\"2024\">Doen\u00e7as neuromusculares graves;<\/p>\n<\/li>\n<li data-start=\"2025\" data-end=\"2044\">\n<p data-start=\"2027\" data-end=\"2044\">S\u00edndrome de Down;<\/p>\n<\/li>\n<li data-start=\"2045\" data-end=\"2084\">\n<p data-start=\"2047\" data-end=\"2084\">Anomalias cong\u00eanitas das vias a\u00e9reas;<\/p>\n<\/li>\n<li data-start=\"2085\" data-end=\"2113\">\n<p data-start=\"2087\" data-end=\"2113\">Doen\u00e7as pulmonares graves.<\/p>\n<\/li>\n<\/ul>\n<hr data-start=\"2115\" data-end=\"2118\" \/>\n<h2 style=\"text-align: justify;\" data-start=\"2120\" data-end=\"2145\">Como acessar o servi\u00e7o<\/h2>\n<p style=\"text-align: justify;\" data-start=\"2147\" data-end=\"2279\">Os respons\u00e1veis devem procurar a unidade da Estrat\u00e9gia de Sa\u00fade da Fam\u00edlia (ESF) de refer\u00eancia e apresentar os seguintes documentos:<\/p>\n<ul style=\"text-align: justify;\" data-start=\"2281\" data-end=\"2343\">\n<li data-start=\"2281\" data-end=\"2316\">\n<p data-start=\"2283\" data-end=\"2316\">Carteira de vacina\u00e7\u00e3o da crian\u00e7a;<\/p>\n<\/li>\n<li data-start=\"2317\" data-end=\"2343\">\n<p data-start=\"2319\" data-end=\"2343\">Laudo m\u00e9dico atualizado.<\/p>\n<\/li>\n<\/ul>\n<hr data-start=\"2345\" data-end=\"2348\" \/>\n<p style=\"text-align: justify;\" data-start=\"2350\" data-end=\"2410\"><strong data-start=\"2350\" data-end=\"2365\">Refer\u00eancia:<\/strong> Norma T\u00e9cnica n\u00ba 109\/2025-CGICI\/DPNI\/SVSA\/MS<\/p>\n<p data-start=\"2350\" data-end=\"2410\">\n<p data-start=\"2350\" data-end=\"2410\"><strong>Segue Cronograma de Vacina\u00e7\u00e3o:<\/strong><\/p>\n<p data-start=\"2350\" data-end=\"2410\"><strong><a href=\"http:\/\/www.terenos.ms.gov.br\/wp-content\/uploads\/calendario-vacinal-2026.pdf\">calend\u00e1rio vacinal 2026<\/a><\/strong><\/p>\n<p data-start=\"2350\" data-end=\"2410\"><strong>Segue resolu\u00e7\u00e3o Palivizumabe:<\/strong><\/p>\n<p data-start=\"2350\" data-end=\"2410\"><a href=\"http:\/\/www.terenos.ms.gov.br\/wp-content\/uploads\/RESOLUCAO-CIBSES-N.-579-13.02.25-Palivizumabe.pdf\">RESOLU\u00c7\u00c3O CIBSES N. 579, 13.02.25- Palivizumabe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Prote\u00e7\u00e3o contra o V\u00edrus Sincicial Respirat\u00f3rio (VSR) em crian\u00e7as O Palivizumabe \u00e9 um anticorpo monoclonal indicado para a preven\u00e7\u00e3o de infec\u00e7\u00f5es graves causadas pelo V\u00edrus Sincicial Respirat\u00f3rio (VSR), especialmente em crian\u00e7as que apresentam maior risco de complica\u00e7\u00f5es. Continuidade do uso do Palivizumabe Devem concluir obrigatoriamente o esquema com Palivizumabe: Crian\u00e7as prematuras nascidas com idade gestacional [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":8509,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[14],"tags":[],"class_list":["post-8506","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-saude"],"_links":{"self":[{"href":"https:\/\/www.terenos.ms.gov.br\/index.php?rest_route=\/wp\/v2\/posts\/8506","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.terenos.ms.gov.br\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.terenos.ms.gov.br\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.terenos.ms.gov.br\/index.php?rest_route=\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.terenos.ms.gov.br\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=8506"}],"version-history":[{"count":1,"href":"https:\/\/www.terenos.ms.gov.br\/index.php?rest_route=\/wp\/v2\/posts\/8506\/revisions"}],"predecessor-version":[{"id":8510,"href":"https:\/\/www.terenos.ms.gov.br\/index.php?rest_route=\/wp\/v2\/posts\/8506\/revisions\/8510"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.terenos.ms.gov.br\/index.php?rest_route=\/wp\/v2\/media\/8509"}],"wp:attachment":[{"href":"https:\/\/www.terenos.ms.gov.br\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=8506"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.terenos.ms.gov.br\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=8506"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.terenos.ms.gov.br\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=8506"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}